Curbside Consults Podcast
Published January 28, 2021
Inhibitors of sodium–glucose cotransporter 2 (SGLT2) are known to improve cardiovascular and renal outcomes in patients with type 2 diabetes. Until recently, less was known about the effects of SGLT2 inhibitors on heart failure. In this episode of Curbside Consults, we are joined by Dr. John McMurray, Professor of Cardiology and the lead investigator of the DAPA-HF trial, to discuss the benefits of SGLT2 inhibitors in patients with heart failure.
0:00 – Intro
1:32 – Background of trials in SGLT2 inhibitors and heart failure
3:20 – Mechanism of action of SGLT2 inhibitors in heart failure treatment
5:05 – DAPA-HF trial
6:48 – EMPEROR-Reduced and the SOLOIST-WHF trials
9:40 – Composite outcomes in heart failure trials
13:14 – Indications for SGLT2 inhibitors in heart failure
15:10 – SGLT2 inhibitors and heart failure treatment algorithms
17:00 – Hypoglycemia risk
20:10 – End
Resources and articles discussed in this episode:
1. McMurray J. et al Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction N Eng J Med 2019.
2. Bhatt D. et al Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure N Eng J Med 2020.
3. Packer M. et al Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure N Eng J Med 2020.
4. Jarcho J. More Evidence for SGLT2 Inhibitors in Heart Failure N Eng J Med 2020.
The Curbside Consults series complements the foundational information in Rotation Prep by taking a deep dive into key clinical topics with expert clinicians and educators. These podcasts explore and critique the evidence behind clinical practice and break down statistical concepts for the busy clinical trainee.